Page last updated: 2024-11-04

sumatriptan and Itching

sumatriptan has been researched along with Itching in 3 studies

Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.

Research Excerpts

ExcerptRelevanceReference
" Migraine-associated gastroparesis can impair absorption and reduce bioavailability of oral migraine medications and thereby reduce and delay therapeutic efficacy."2.77Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. ( Goldstein, J; Pierce, MW; Pugach, N; Silberstein, S; Singer, R; Smith, TR, 2012)
"Chloroquine was injected intradermally into the rostral back of NMRI mice, and the scratching behavior was evaluated by measuring the number of bouts over 30 min."1.48Pharmacological evidence of involvement of nitric oxide pathway in anti-pruritic effects of sumatriptan in chloroquine-induced scratching in mice. ( Afshari, K; Dehpour, AR; Foroutan, A; Haddadi, NS; Ostadhadi, S; Rahimi, N; Shakiba, S, 2018)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Haddadi, NS2
Ostadhadi, S2
Shakiba, S2
Afshari, K2
Rahimi, N1
Foroutan, A2
Dehpour, AR2
Daneshpazhooh, M1
Smith, TR1
Goldstein, J1
Singer, R1
Pugach, N1
Silberstein, S1
Pierce, MW1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months[NCT00792103]Phase 3198 participants (Actual)Interventional2009-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Nausea Free

Nausea free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours

Interventionparticipants (Number)
NP101143

Pain Relief

Headache pain relief (no pain or mild headache pain) at two hours post activation of NP101. (NCT00792103)
Timeframe: 2 hours

Interventionparticipants (Number)
NP101105

Phonophobia Free

Phonophobia free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours

Interventionparticipants (Number)
NP101109

Photophobia Free

Photophobia free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours

Interventionparticipant (Number)
NP10197

Subject Self-examination of Skin Irritation

For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin). (NCT00792103)
Timeframe: 24 hours post patch activation

Interventionscores on a scale (Mean)
NP1011.0

Trials

1 trial available for sumatriptan and Itching

ArticleYear
Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system.
    Headache, 2012, Volume: 52, Issue:4

    Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Chemistry, Pharmaceutical; Female; Follow-Up Stu

2012

Other Studies

2 other studies available for sumatriptan and Itching

ArticleYear
Pharmacological evidence of involvement of nitric oxide pathway in anti-pruritic effects of sumatriptan in chloroquine-induced scratching in mice.
    Fundamental & clinical pharmacology, 2018, Volume: 32, Issue:1

    Topics: Animals; Antipruritics; Behavior, Animal; Chloroquine; Disease Models, Animal; Dose-Response Relatio

2018
Attenuation of serotonin-induced itch by sumatriptan: possible involvement of endogenous opioids.
    Archives of dermatological research, 2018, Volume: 310, Issue:2

    Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Humans; Injections, Intradermal; Male; M

2018